Sep 12, 2022 / 06:15PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Okay. Great. Thanks for joining us, everybody. I'm Terence Flynn, the pharma analyst -- U.S. pharma analyst here at Morgan Stanley. We're very pleased to have Merck with us today.
For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com\researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Joining us today from the company, we have Rob Davis, CEO; and Dean Li, Head of R&D. Thank you, gentlemen, for joining us today. Really great to be back in person, and great to have you here today.
Robert M. Davis - Merck & Co., Inc. - President, CEO & Director
Great. Thank you for having us. It's good to be back in person.
Questions and Answers:
Terence C. Flynn - Morgan Stanley, Research Division - Equity AnalystFor sure. Maybe, Rob, obviously, newly recently appointed CEO, maybe just help us think